Therapy Directory

Nivolumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Nivolumab as a study intervention. Browse Nivolumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Jun 2, 2026, 12:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

672

Shown on this page

Local indexed summaries

672

Local recruiting

136

The trial list below is retrieved from the live ClinicalTrials.gov search API for Nivolumab. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 672 matching trials for Nivolumab.

Indexed local directory records.

Top conditions

Melanoma 47 Metastatic Melanoma 38 Renal Cell Carcinoma 28 Hepatocellular Carcinoma 21 Non-small Cell Lung Cancer 19 Solid Tumor 19

Top sponsors

National Cancer Institute (NCI) 76 Bristol-Myers Squibb 68 M.D. Anderson Cancer Center 48 H. Lee Moffitt Cancer Center and Research Institute 22 Memorial Sloan Kettering Cancer Center 22 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 21

Top locations

New York, New York 215 Houston, Texas 200 Boston, Massachusetts 171 Chicago, Illinois 151 Los Angeles, California 144 Philadelphia, Pennsylvania 125

Indexed official records

Open in full search

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive
Interventions: Brentuximab vedotin (Adcetris), Nivolumab (Opdivo), Vinblastine (Velban); Drug
Lead sponsor: New York Medical College; Other
Eligibility: 1 Year to 39 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Carboplatin, Cisplatin, Nivolumab, Pembrolizumab, Pemetrexed, Relatlimab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 45
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 42 more

Conditions: Renal Cell Carcinoma
Interventions: Nivolumab, Tivozanib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Irvine, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions: Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab, cfDNA or ctDNA Measurement; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 487
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 367 more

Conditions: EBV/KSHV-associated Lymphomas, Kaposi Sarcoma, Viral Associated Malignancies
Interventions: Nivolumab, Pomalidomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Chest Radiography, Cisplatin, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Fluciclovine F18, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, X-Ray Imaging; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 76
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more

Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Carboplatin, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Relatlimab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 74
States / cities: Dublin, California • Fremont, California • Fresno, California + 57 more

Conditions: Metastatic Melanoma, Skin Cancer
Interventions: Cryoablation, Ipilimumab, Nivolumab; Procedure · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Melanoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Unresectable Melanoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 222
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 173 more

Conditions: Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions: Nivolumab, XL092; Drug
Lead sponsor: Karie Runcie; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: La Jolla, California • Indianapolis, Indiana • St Louis, Missouri + 1 more

Conditions: Brain Metastases, Melanoma
Interventions: Ipilimumab, Nivolumab + Relatlimab FDC; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Melanoma
Interventions: Ipilimumab, Nivolumab; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Salt Lake City, Utah

About this Nivolumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Nivolumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Nivolumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Nivolumab clinical trials

Filter and sort this therapy

Top conditions

Top sponsors

Top locations

Indexed official records

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Cryoablation+Ipilimumab+Nivolumab in Melanoma

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

About this Nivolumab clinical trials directory page